Introducing Novel Molecular-based Method for Quantification of Homologous Recombination Efficiency
Abstract
BackgroundHomologous recombination (HR) pathway is a DNA double-stranded breaks repair pathway well-known for its high level of accuracy. Low HR pathway efficiency clinically known as homologous recombination deficiency (HRD) was identified in some cancers such as breast and ovarian cancers and studies have reported the sensitivity of HRD cancer cells to DNA repair inhibitors such as Olaparib. However, current techniques including immunofluorescence-based technique are qualitative-based, hence lack sensitivity to determine the functionality of HR pathway. Additionally, some of the techniques including gene expression arrays require expression study of wide range genes involve in HR pathway, which is not cost-effective. The aim of the study is to optimise a PCR-based assay (Norgens Homologous Recombination kit) that can be employed to quantitate HR efficiency in cells, which accurately reflects the functional status of HR pathway. Methods and FindingsThe kit has two test plasmids (dl-1 and dl-2) with partial deletions in the LacZ gene and the plasmids are generated from modification of pUC19. HR-proficient (HeLa and AsPC-1) and HR-deficient (CAPAN-1 cells) cancer cell lines were transfected with the two plasmids to generate functional LacZ gene (i.e. recombinant product). The recombinant product was quantified by real-time PCR. Although recombinant product was generated in all the cell lines, our real-time PCR demonstrated a high quantity of recombinant product in HeLa cell line whilst low quantity in CAPAN-1 and AsPC-1 cell lines. The quantity of recombinant product generated and quantified reflects HR pathway efficiency. ConclusionOverall, the results have provided some evidence that the PCR-based kit can be suitably employed for quantification of HR efficiency provided appropriate transfection method and reagent are used. However, further study is required to confirm HR efficiency status of AsPC-1 cells to ascertain the low HR efficiency detected by the kit in these cells.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pan-cancer Analysis of Homologous Recombination Deficiency in Cell Lines
Anne E. Dodson, Sol Shenker, … Dipen P. Sangurdekar·Cancer Research CommunicationsPeer-reviewed·Nov 1, 2024
- HRD-One: CLINICAL VALIDATION AND PERFORMANCE ASSESSMENT. Comparison between Myriad's myChoice(R), SOPHiA GENETICS SOPHiA Homologous Recombination Solution(R) and AmoyDx HRD Focus Panel(R)
Rodrigo Guarischi‐Sousa, José Eduardo Kroll, … Guilherme Lopes Yamamoto·medRxiv·Mar 28, 2023
- Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer Cohort
Majd Al Assaad, Kevin Hadi, … Juan Miguel Mosquera·medRxiv·Jun 28, 2024
- RepairSwitch: simultaneous functional assessment of homologous recombination and end joining DNA repair pathways in living cells
R. C. Steinberg, J. Liu, … S. Yegnasubramanian·bioRxiv·Jan 17, 2023
- Optimized detection of allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in cancer
F. Perez-Villatoro, J. Oikkonen, … A. Farkkila·bioRxiv·Aug 19, 2021
- Automated Machine Learning Profiling with MAP-HR for Quantifying Homologous Recombination Foci in Patient Samples
Tugba Y. Ozmen, Matthew J. Rames, … Gordon Brent Mills·NAR CancerPeer-reviewed·Jul 29, 2025